These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Disorders of fat partitioning in treated HIV-infection. Martínez E Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):415-27. PubMed ID: 21663836 [TBL] [Abstract][Full Text] [Related]
3. [Lipodystrophies related to antiretroviral treatment of HIV infection]. Capeau J; Caron M; Vigouroux C; Cervera P; Kim M; Maachi M; Lagathu C; Bastard JP Med Sci (Paris); 2006 May; 22(5):531-6. PubMed ID: 16687123 [TBL] [Abstract][Full Text] [Related]
4. A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Kim MJ; Leclercq P; Lanoy E; Cervera P; Antuna-Puente B; Maachi M; Dorofeev E; Slama L; Valantin MA; Costagliola D; Lombes A; Bastard JP; Capeau J Antivir Ther; 2007; 12(8):1273-83. PubMed ID: 18240867 [TBL] [Abstract][Full Text] [Related]
5. [Metabolic side effects of antiretroviral therapy]. van der Valk M; Reiss P Ned Tijdschr Geneeskd; 2008 May; 152(22):1260-4. PubMed ID: 18590059 [TBL] [Abstract][Full Text] [Related]
7. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Lagathu C; Kim M; Maachi M; Vigouroux C; Cervera P; Capeau J; Caron M; Bastard JP Biochimie; 2005 Jan; 87(1):65-71. PubMed ID: 15733739 [TBL] [Abstract][Full Text] [Related]
8. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704 [TBL] [Abstract][Full Text] [Related]
9. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Nolan D; Hammond E; James I; McKinnon E; Mallal S Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896 [TBL] [Abstract][Full Text] [Related]
10. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860 [TBL] [Abstract][Full Text] [Related]
11. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178 [TBL] [Abstract][Full Text] [Related]
12. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1H-MR spectroscopy. Moreno-Torres A; Domingo P; Pujol J; Blanco-Vaca F; Arroyo JA; Sambeat MA Antivir Ther; 2007; 12(2):195-203. PubMed ID: 17503662 [TBL] [Abstract][Full Text] [Related]
13. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Caron M; Auclairt M; Vissian A; Vigouroux C; Capeau J Antivir Ther; 2008; 13(1):27-38. PubMed ID: 18389896 [TBL] [Abstract][Full Text] [Related]
14. Uridine supplementation for the treatment of antiretroviral therapy-associated lipoatrophy: a randomized, double-blind, placebo-controlled trial. Sutinen J; Walker UA; Sevastianova K; Klinker H; Häkkinen AM; Ristola M; Yki-Järvinen H Antivir Ther; 2007; 12(1):97-105. PubMed ID: 17503753 [TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of a growth hormone-releasing factor in patients with HIV. Falutz J; Allas S; Blot K; Potvin D; Kotler D; Somero M; Berger D; Brown S; Richmond G; Fessel J; Turner R; Grinspoon S N Engl J Med; 2007 Dec; 357(23):2359-70. PubMed ID: 18057338 [TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy. Zanone Poma B; Riva A; Nasi M; Cicconi P; Broggini V; Lepri AC; Mologni D; Mazzotta F; Monforte AD; Mussini C; Cossarizza A; Galli M; AIDS; 2008 Sep; 22(14):1769-78. PubMed ID: 18753860 [TBL] [Abstract][Full Text] [Related]
17. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. Buffet M; Schwarzinger M; Amellal B; Gourlain K; Bui P; Prévot M; Deleuze J; Morini JP; Gorin I; Calvez V; Dupin N J Clin Virol; 2005 May; 33(1):60-4. PubMed ID: 15797366 [TBL] [Abstract][Full Text] [Related]
18. Adipocyte dysfunction in response to antiretroviral therapy: clinical, tissue and in-vitro studies. Caron M; Vigouroux C; Bastard JP; Capeau J Curr Opin HIV AIDS; 2007 Jul; 2(4):268-73. PubMed ID: 19372898 [TBL] [Abstract][Full Text] [Related]
19. Adipose tissue as a target of HIV-1 antiretroviral drugs. Potential consequences on metabolic regulations. Caron-Debarle M; Boccara F; Lagathu C; Antoine B; Cervera P; Bastard JP; Vigouroux C; Capeau J Curr Pharm Des; 2010 Oct; 16(30):3352-60. PubMed ID: 20687886 [TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. Cavalcanti RB; Raboud J; Shen S; Kain KC; Cheung A; Walmsley S J Infect Dis; 2007 Jun; 195(12):1754-61. PubMed ID: 17492590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]